| For: | Lai GM, Yan SL, Chang CS, Tsai CY. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol 2013; 19(8): 1318-1321 [PMID: 23483799 DOI: 10.3748/wjg.v19.i8.1318] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v19/i8/1318.htm |
| Number | Citing Articles |
| 1 |
Stevan A. Gonzalez, Robert P. Perrillo. Hepatitis B Virus in Human Diseases. Molecular and Translational Medicine 2016; doi: 10.1007/978-3-319-22330-8_18
|
| 2 |
Rohit Loomba, T. Jake Liang. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology 2017; 152(6) doi: 10.1053/j.gastro.2017.02.009
|
| 3 |
Venessa Pattullo. Prevention of Hepatitis B reactivation in the setting of immunosuppression. Clinical and Molecular Hepatology 2016; 22(2) doi: 10.3350/cmh.2016.0024
|
| 4 |
Jun Cheng, Jinjin Pan, Dongmei Zhao, Xuejiao Ma, Qiulin Sun, Jiabin Li. HCV Reactivation in a Patient with Hepatocellular Carcinoma Due to Sorafenib: A Case Report. International Medical Case Reports Journal 2024; doi: 10.2147/IMCRJ.S444521
|
| 5 |
Mar Riveiro-Barciela, Paula Gubern, Luisa Roade, Pau Abrisqueta, María José Carreras, Anna Farriols, Francesc Bosch, Rafael Esteban, María Buti. An electronic alert system increases screening for hepatitis B and C and improves management of patients with haematological disorders. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-59476-4
|
| 6 |
Ling‐Yi Wang, Sung‐Chao Chu, I‐Yun Chang, K. Arnold Chan. Sex‐specific incidence of hepatitis B virus flares among Bcr‐Abl tyrosine kinase inhibitor users in Taiwan. Pharmacoepidemiology and Drug Safety 2023; 32(12) doi: 10.1002/pds.5667
|
| 7 |
Toshihiko Ando, Kensuke Kojima, Hiroshi Isoda, Yuichiro Eguchi, Takashi Honda, Masatoshi Ishigami, Shinya Kimura. Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia. International Journal of Hematology 2015; 102(3) doi: 10.1007/s12185-015-1788-y
|
| 8 |
Gian Paolo Caviglia, Antonella Zorzi, Mario Rizzetto, Massimo Mirandola, Antonella Olivero, Giada Carolo. Hepatitis B Virus Reactivation upon Immunosuppression: Is There a Role for Hepatitis B Core-Related Antigen in Patients with Immune-Escape Mutants? A Case Report. Diagnostics 2021; 11(12) doi: 10.3390/diagnostics11122185
|
| 9 |
Yu-Hung Wang, Ja-Der Liang, Wang-Huei Sheng, Feng-Ming Tien, Chien-Yuan Chen, Hwei-Fang Tien. Hepatitis B reactivation during treatment of tyrosine kinase inhibitors—Experience in 142 adult patients with chronic myeloid leukemia. Leukemia Research 2019; 81 doi: 10.1016/j.leukres.2019.05.001
|
| 10 |
Andreas Panagopoulos, Stavros Taraviras, Hideo Nishitani, Zoi Lygerou. CRL4Cdt2: Coupling Genome Stability to Ubiquitination. Trends in Cell Biology 2020; 30(4) doi: 10.1016/j.tcb.2020.01.005
|
| 11 |
Bee Kim Tan, Siew Siang Chua, Li-Chia Chen, Kian Meng Chang, Sharmini Balashanker, Ping Chong Bee. Acceptability of pharmacist-led interventions to resolve drug-related problems in patients with chronic myeloid leukaemia. Journal of Oncology Pharmacy Practice 2021; 27(7) doi: 10.1177/1078155220964539
|
| 12 |
Robert P. Perrillo, Robert Gish, Yngve T. Falck-Ytter. American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy. Gastroenterology 2015; 148(1) doi: 10.1053/j.gastro.2014.10.038
|
| 13 |
Christos Koutsianas, Konstantinos Thomas, Dimitrios Vassilopoulos. Hepatitis B Reactivation in Rheumatic Diseases. Rheumatic Disease Clinics of North America 2017; 43(1) doi: 10.1016/j.rdc.2016.09.012
|
| 14 |
L. Sarmati, M. Andreoni, G. Antonelli, W. Arcese, R. Bruno, N. Coppola, G.B. Gaeta, M. Galli, C. Girmenia, M. Mikulska, F. Pane, C.F. Perno, M. Picardi, M. Puoti, A. Rambaldi, V. Svicher, G. Taliani, G. Gentile. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper. Clinical Microbiology and Infection 2017; 23(12) doi: 10.1016/j.cmi.2017.06.023
|
| 15 |
Tuncer Temel, Eren Gunduz, Esmira Sadigova, Hava Uskudar Teke, Safak Meric Ozgenel, Aysegul Harmanci Ozakyol. Hepatitis B Virus Reactivation under
Treatment with Nilotinib. Euroasian Journal of Hepato-Gastroenterology 2015; 5(2) doi: 10.5005/jp-journals-10018-1147
|
| 16 |
M. Reinwald, J.T. Silva, N.J. Mueller, J. Fortún, C. Garzoni, J.W. de Fijter, M. Fernández-Ruiz, P. Grossi, J.M. Aguado. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clinical Microbiology and Infection 2018; 24 doi: 10.1016/j.cmi.2018.02.009
|
| 17 |
Alessandra Tedeschi, Anna Maria Frustaci, Maddalena Mazzucchelli, Roberto Cairoli, Marco Montillo. Is HBV prophylaxis required during CLL treatment with ibrutinib?. Leukemia & Lymphoma 2017; 58(12) doi: 10.1080/10428194.2017.1317094
|
| 18 |
Shang-Chin Huang, Hung-Chih Yang, Jia-Horng Kao. Hepatitis B reactivation: diagnosis and management. Expert Review of Gastroenterology & Hepatology 2020; 14(7) doi: 10.1080/17474124.2020.1774364
|
| 19 |
Xiaoming Cheng, Takuro Uchida, Yuchen Xia, Regina Umarova, Chun-Jen Liu, Pei-Jer Chen, Anuj Gaggar, Vithika Suri, Marcus M. Mücke, Johannes Vermehren, Stefan Zeuzem, Yuji Teraoka, Mitsutaka Osawa, Hiroshi Aikata, Keiji Tsuji, Nami Mori, Shuhei Hige, Yoshiyasu Karino, Michio Imamura, Kazuaki Chayama, T. Jake Liang. Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. Journal of Clinical Investigation 2020; 130(6) doi: 10.1172/JCI135616
|
| 20 |
Venessa Pattullo. Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure. World Journal of Hepatology 2015; 7(7): 954-967 doi: 10.4254/wjh.v7.i7.954
|
| 21 |
Muhsin Kaya, Recai Akdogan, Feyzullah Uçmak, Mehmet O Ayyildiz, Abdullah Karakus, Muhammet A Kaplan. The Incidence and Predictive Factors in the Development of Acute Hepatitis in Patients with Leukemia. Euroasian Journal of Hepato-Gastroenterology 2018; 8(1) doi: 10.5005/jp-journals-10018-1254
|
| 22 |
Tian Yu, Weiming Li, Tao Yu. Management of chronic myelogenous leukemia with COVID-19 and hepatitis B. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1217023
|
| 23 |
Kirsty Wai-Chung Lee, Stephen Lam Chan. Hepatotoxicity of targeted therapy for cancer. Expert Opinion on Drug Metabolism & Toxicology 2016; 12(7) doi: 10.1080/17425255.2016.1190831
|
| 24 |
Shady Adnan Awad, Matti Kankainen, Teija Ojala, Perttu Koskenvesa, Samuli Eldfors, Bishwa Ghimire, Ashwini Kumar, Soili Kytölä, Mahmoud M. Kamel, Caroline A. Heckman, Kimmo Porkka, Satu Mustjoki. Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. Blood Advances 2020; 4(3) doi: 10.1182/bloodadvances.2019000943
|
| 25 |
Ling-Yi Wang, Sung-Chao Chu, Yin Lo, Yen-Yun Yang, K. Arnold Chan. Association of Bcr-Abl Tyrosine Kinase Inhibitors With Hepatitis B Virus Reactivation Requiring Antiviral Treatment in Taiwan. JAMA Network Open 2021; 4(4) doi: 10.1001/jamanetworkopen.2021.4132
|
| 26 |
Federica Sorà, Francesca Romana Ponziani, Luca Laurenti, Patrizia Chiusolo, Francesco Autore, Antonio Gasbarrini, Simona Sica, Maurizio Pompili. Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors. Leukemia & Lymphoma 2017; 58(4) doi: 10.1080/10428194.2016.1219906
|
| 27 |
Lidan Hou, Jie Zhao, Shaobing Gao, Tong Ji, Tianyu Song, Yining Li, Jingjie Wang, Chenlu Geng, Min Long, Jiang Chen, Hui Lin, Xiujun Cai, Yong Cang. Restriction of hepatitis B virus replication by c-Abl–induced proteasomal degradation of the viral polymerase. Science Advances 2019; 5(2) doi: 10.1126/sciadv.aau7130
|
| 28 |
Asmaa Atteya, Aiman Ahmad, Dima Daghstani, Kamran Mushtaq, Mohamed A. Yassin. Evaluation of Hepatitis B Reactivation Among Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. Cancer Control 2020; 27(1) doi: 10.1177/1073274820976594
|
| 29 |
Young Chang, Soung Won Jeong, Jae Young Jang. Hepatitis B Virus Reactivation Associated With Therapeutic Interventions. Frontiers in Medicine 2022; 8 doi: 10.3389/fmed.2021.770124
|
| 30 |
S. Yazaki, T. Yamauchi, T. Higashi. High hepatitis B virus screening rate among patients receiving systemic anticancer treatment in Japan. International Journal of Clinical Oncology 2020; 25(7) doi: 10.1007/s10147-020-01655-4
|
| 31 |
Bettina M. Knoll, K. Seiter. Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature. Infection 2018; 46(3) doi: 10.1007/s15010-017-1105-1
|
| 32 |
Mark Reinwald, Tobias Boch, Wolf-Karsten Hofmann, Dieter Buchheidt. Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. Biomarker Insights 2015; doi: 10.4137/BMI.S22430
|
| 33 |
Mauro Viganò, Giuseppe Serra, Giovanni Casella, Glenda Grossi, Pietro Lampertico. Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders. Expert Opinion on Biological Therapy 2016; 16(7) doi: 10.1080/14712598.2016.1177017
|
| 34 |
Ester Maria Orlandi, Chiara Elena, Elisa Bono. Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia. Leukemia & Lymphoma 2017; 58(7) doi: 10.1080/10428194.2016.1260127
|
| 35 |
Oscar Marchetti, Frederic Tissot, Thierry Calandra. Infectious Diseases. 2017; doi: 10.1016/B978-0-7020-6285-8.00079-4
|
| 36 |
Faisal Inayat, Fei Song, Nouman Safdar Ali, Muhammad Haseeb Aslam, Aishatu Aloma, Hilal Hachem, Muhammad Wasif Saif. Hepatitis B virus reactivation following imatinib therapy: A comparative review of 9 cases. Journal of Oncology Pharmacy Practice 2019; 25(6) doi: 10.1177/1078155218790337
|
| 37 |
Giuseppe Indolfi, Mona Abdel‐Hady, Sanjay Bansal, Dominique Debray, Françoise Smets, Piotr Czubkowski, Wendy van der Woerd, Marianne Samyn, Jörg Jahnel, Girish Gupte, Aglaia Zellos, Yael Mozer‐Glassberg, Henkjan J. Verkade, Etienne Sokal, Björn Fischler. Management of Hepatitis B Virus Infection and Prevention of Hepatitis B Virus Reactivation in Children With Acquired Immunodeficiencies or Undergoing Immune Suppressive, Cytotoxic, or Biological Modifier Therapies. Journal of Pediatric Gastroenterology and Nutrition 2020; 70(4) doi: 10.1097/MPG.0000000000002628
|
| 38 |
Sarah Atkins, Fiona He. Chemotherapy and Beyond. Infectious Disease Clinics of North America 2019; 33(2) doi: 10.1016/j.idc.2019.01.001
|
| 39 |
Delphine Rea. Chronic Myeloid Leukemia. Hematologic Malignancies 2021; doi: 10.1007/978-3-030-71913-5_6
|
| 40 |
|
| 41 |
Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association, Hui Cao, Jian Pan, Mei-Xia Zhang, Wei-Jun Gu, Dong Zhang, Ping Lu, Jing Zou, Li-Jing Shen, Hao Xu, Xin-Hua Zhang, Ye Zhou, Xiu-Feng Liu, Tian-Long Lin, Xin Wu, Bo Zhang, Ming Wang, Jian Li. Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors. World Journal of Gastroenterology 2018; 24(46): 5189-5202 doi: 10.3748/wjg.v24.i46.5189
|
| 42 |
Ka-Shing Cheung, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen. Prevention and management of hepatitis B virus reactivation in cancer patients. Hepatology International 2016; 10(3) doi: 10.1007/s12072-015-9692-3
|
| 43 |
Mansour Tobaiqy, Nawal Helmi, Katie MacLure, Sylvia Saade. The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review. International Journal of Clinical Pharmacy 2024; 46(2) doi: 10.1007/s11096-023-01671-0
|
| 44 |
Tommy HC Tam, Joyce Ng, Jennifer Lai, Jacqueline So, Bonaventure Ip, Kent CY So, Karen Ma, Lydia HP Tam, Carmen KM Cheung, Rita Ho, Man Fai Law. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World Journal of Gastroenterology 2016; 22(28): 6484-6500 doi: 10.3748/wjg.v22.i28.6484
|
| 45 |
Ivan Noreña, Mario Fernández-Ruiz, José María Aguado. Viral infections in the biologic therapy era. Expert Review of Anti-infective Therapy 2018; 16(10) doi: 10.1080/14787210.2018.1521270
|
| 46 |
C.S. Voican, O. Mir, P. Loulergue, M. Dhooge, C. Brezault, J. Dréanic, S. Chaussade, S. Pol, R. Coriat. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Annals of Oncology 2016; 27(12) doi: 10.1093/annonc/mdw414
|
| 47 |
Maria V. Konopleva, Maxim S. Belenikin, Andrei V. Shanko, Alexey I. Bazhenov, Sergei A. Kiryanov, Tatyana A. Tupoleva, Maria V. Sokolova, Alexander V. Pronin, Tatyana A. Semenenko, Anatoly P. Suslov. Detection of S-HBsAg Mutations in Patients with Hematologic Malignancies. Diagnostics 2021; 11(6) doi: 10.3390/diagnostics11060969
|
| 48 |
Akimasa Sanagawa, Yuji Hotta, Tomoya Kataoka, Yasuhiro Maeda, Masahiro Kondo, Yoshihiro Kawade, Yoshihiro Ogawa, Ryohei Nishikawa, Masahiro Tohkin, Kazunori Kimura. Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System. Cancer Medicine 2018; 7(6) doi: 10.1002/cam4.1429
|
| 49 |
Hidekazu Itamura, Yasushi Kubota, Takero Shindo, Toshihiko Ando, Kensuke Kojima, Shinya Kimura. Elderly Patients With Chronic Myeloid Leukemia Benefit From a Dasatinib Dose as Low as 20 mg. Clinical Lymphoma Myeloma and Leukemia 2017; 17(6) doi: 10.1016/j.clml.2017.02.023
|
| 50 |
Christos Koutsianas, Konstantinos Thomas, Dimitrios Vassilopoulos. Prevention of HBV reactivation in patients treated with biologic agents. Expert Review of Clinical Pharmacology 2016; 9(4) doi: 10.1586/17512433.2016.1143773
|
| 51 |
Sirina Ekpanyapong, K. Rajender Reddy. Hepatitis B Virus Reactivation. Clinics in Liver Disease 2020; 24(3) doi: 10.1016/j.cld.2020.04.002
|
| 52 |
Cheng-Shyong Chang, Chien-Yu Tsai, Sheng-Lei Yan. Hepatitis B reactivation in patients receiving targeted therapies. Hematology 2017; 22(10) doi: 10.1080/10245332.2017.1321882
|
| 53 |
Joshua S. Davis, David Ferreira, Emma Paige, Craig Gedye, Michael Boyle. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clinical Microbiology Reviews 2020; 33(3) doi: 10.1128/CMR.00035-19
|
| 54 |
Wai-Kay Seto. Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. World Journal of Hepatology 2015; 7(6): 825-830 doi: 10.4254/wjh.v7.i6.825
|
| 55 |
Rajneesh Kumar, Clement Chun-Ho Wu. Hepatitis B reactivation in patients with hepatitis B core antibody positive and surface antigen negative on immunosuppressants. World Journal of Meta-Analysis 2019; 7(5): 209-217 doi: 10.13105/wjma.v7.i5.209
|